A number of other research firms have also recently weighed in on FTSV. SunTrust Banks cut Forty Seven from a buy rating to a hold rating and lifted their price target for the company from $55.00 to $95.50 in a report on Tuesday, March 3rd. Mizuho cut Forty Seven from a buy rating to a neutral rating and set a $95.50 price target on the stock. in a report on Wednesday, March 4th. Morgan Stanley cut Forty Seven from an overweight rating to an equal weight rating and lifted their price target for the company from $45.00 to $95.50 in a report on Tuesday, March 3rd. Credit Suisse Group reaffirmed an outperform rating and set a $18.00 price target (up previously from $15.00) on shares of Forty Seven in a report on Thursday, December 5th. Finally, Guggenheim cut Forty Seven from a buy rating to a neutral rating in a report on Tuesday, March 3rd. Eight investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Forty Seven currently has a consensus rating of Hold and an average target price of $69.86.
Shares of FTSV traded up $0.05 during mid-day trading on Thursday, reaching $95.51. 693,725 shares of the company’s stock traded hands, compared to its average volume of 1,607,076. The business’s 50-day moving average price is $77.63 and its 200-day moving average price is $36.04. The stock has a market capitalization of $4.60 billion, a P/E ratio of -38.67 and a beta of 0.40. Forty Seven has a 12 month low of $5.53 and a 12 month high of $95.51.
A number of institutional investors have recently bought and sold shares of FTSV. RA Capital Management L.P. acquired a new position in Forty Seven in the fourth quarter worth approximately $76,112,000. Lord Abbett & CO. LLC acquired a new stake in shares of Forty Seven in the 4th quarter valued at $18,954,000. FMR LLC lifted its stake in shares of Forty Seven by 419.4% in the 4th quarter. FMR LLC now owns 593,659 shares of the company’s stock valued at $23,372,000 after purchasing an additional 479,359 shares during the last quarter. Samlyn Capital LLC acquired a new stake in shares of Forty Seven in the 4th quarter valued at $10,777,000. Finally, Driehaus Capital Management LLC acquired a new stake in shares of Forty Seven in the 4th quarter valued at $6,454,000. Hedge funds and other institutional investors own 71.77% of the company’s stock.
About Forty Seven
Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody.
Further Reading: What does a bar chart mean for investors?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.